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Abstract Neuromyelitis optica spectrum disorders (NMOSD) are mostly relapsing inflammatory disorders of the central ner-
vous system (CNS). Optic neuritis (ON) is the first NMOSD-related clinical event in 55% of the patients, which causes damage to
the optic nerve and leads to visual impairment. Retinal optical coherence tomography (OCT) has emerged as a promisingmethod
for diagnosis of NMOSD and potential individual monitoring of disease course and severity. OCT not only detects damage to the
afferent visual system caused by ON but potentially also NMOSD-specific intraretinal pathology, i.e. astrocytopathy. This article
summarizes retinal involvement in NMOSD and reviews OCT methods that could be used now and in the future, for differential
diagnosis, for monitoring of disease course, and in clinical trials.
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Neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders (NMOSD) are auto-
immune inflammatory conditions of the central nervous sys-
tem (CNS) with a mostly relapsing disease course [1]. Clinical
hallmarks of NMOSD are optic neuritis (ON), longitudinally
extensive transverse myelitis (LETM) in the spinal cord span-
ning three or more vertebral segments, and brain stem enceph-
alitis including area postrema syndrome [2–5]. Neuropathic
pain [6], fatigue [7], and depression [8] are important second-
ary symptoms. A serum autoantibody against the astrocytic
water channel, aquaporin-4 (AQP4-ab), is detectable in ap-
proximately 80% of the patients [9–12]. This antibody was
shown to be pathogenic, and its detection together with char-
acteristic clinical, epidemiological, and imaging features al-
lows for the discrimination of NMOSD from multiple sclero-
sis (MS), the most common autoimmune disorder of the CNS
and the most relevant differential disease diagnosis [13–17].
NMOSD has distinct immunopathogenesis from MS, which
firmly establishes both of these conditions as separate noso-
logic entities [18–27]. Consequently, disease-modifying treat-
ment differs fundamentally between NMOSD and MS; as
many drugs used inMS have proven ineffective or even harm-
ful in NMOSD [28–34]. Conversely, many patients with
NMOSD respond well to B cell targeting therapies with ritux-
imab or immunosuppressive therapies with azathioprine or
mycophenolate mofetil [29, 33–37]. Recently, an antibody
against myelin oligodendrocyte glycoprotein (MOG-ab) was
detected in a subgroup of exclusively AQP4-ab seronegative
NMOSD patients [38–44], recurrent idiopathic optic neuritis
(RION) patients, and a fewMS patients [45, 46], further com-
plicating the disease spectrum. Currently, there is controversy
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over whether these MOG-ab seropositive patients are part of
the NMOSD disease spectrum or if they belong to a separate
disease entity (BMOG-ab positive encephalomyelitis^ or
MOG-EM) [47–49]. This article reviews OCT techniques
and discusses associations between structural retinal damage
and visual function in NMOSD. It will also describe the po-
tential future relevance of OCT for differential diagnosis, pa-
tient profiling, individual monitoring of disease course, and
for clinical trials with immunosuppressive or potential causal
therapies. This article is an updated and extended English
version of a recently published article in German [50].
Optical coherence tomography
In vivo imaging of the retinal anatomy by OCT
OCT is an interferometric technique employing low-coherent
light to produce structural cross-sectional images [51]. The
light emitted from the device is backscattered and reflected
in a manner dependent on the structural composition of the
retina; the interference with a reference beam allows anatom-
ical reconstruction with an axial resolution of a few microme-
ters (currently approximately 5 μm) [52, 53]. Since its intro-
duction in 1991 by Huang et al. [54], the OCT research has
been fast paced. Currently, the most widely used OCTsetup is
composed of a fixed reference mirror and simultaneous anal-
ysis of echoes from all retinal layers by Fourier transforma-
tion, thus being called Fourier domain OCT (FD-OCT) or
spectral domain OCT (SD-OCT). SD-OCT achieves highly
reduced motion artifacts, better reproducibility, and 50 to
100 times faster acquisition than previous methods [55–57].
The novel OCT technology involves the use of a short-cavity
swept laser for even higher speed and resolution called swept-
source OCT (SS-OCT) [58], as well as the incorporation of
volumetric angiography images called optical coherence to-
mography angiography (OCTA) [59].
Next to MS and NMOSD, a retinal examination by OCT is
increasingly applied as a non-invasive technique to evaluate
key features of various neurological disorders, e.g., in Susac
syndrome, anti-NMDA receptor encephalitis, and also in neu-
rodegenerative diseases [60–65]. OCT provides high-resolution
3D images of retinal structures and can be employed to evaluate
the first three neurons of the visual pathway and their interneu-
rons, where one key application is the quantification of neuro-
axonal retinal damage (Fig. 1) [66–69].
Retinal layer thinning and its quantification
The peripapillary retinal nerve fiber layer thickness (pRNFL
or sometimes just RNFL or RNFLT) has become a reliable
OCTmarker for diagnostic evaluation in translational research
and care [70–77]. The eponymous retinal nerve fibers are
unmyelinated axons of retinal ganglion cells, originating in
the retina and leaving the eye through the optic nerve head
towards the lateral geniculate nuclei thereby forming the optic
nerve. Therefore, these nerve fibers are a suitable model to
investigate neuro-axonal damage and neuroprotection in dis-
eases presenting with ON, such as NMOSD, where they are
representative of anterograde sections of axons directly affect-
ed by ON [78–81]. The pRNFL is measured in ring scans of
defined circumference (most commonly 12° or 3.5 mm)
around the optic nerve head as mean thickness (in μm)
(Fig. 1). By using a ring scan circling the optic nerve head
virtually, all axons leaving the eye are included in the mea-
surement, thereby allowing representation of the full axonal
















Fig. 1 Anatomy of the retina (a) with corresponding layers measured
by OCT as suggested by Staurenghi et al. [172] and Cruz-Herranz
et al. [97] (b). Parts of the figure are provided by courtesy of www.
neurodial.de [173]. OCT optical coherence tomography, RNFL
retinal nerve fiber layer, GCIP combined ganglion cell and inner
plexiform layer, INL inner nuclear layer, OPL outer plexiform
layer, ONL outer nuclear layer, ELM & MZ external limiting
membrane and myoid zone, OSP outer segments of photoreceptors
(ellipsoid zone), RPE/B retinal pigment epithelium and Bruch’s
complex
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The ganglion cell and inner plexiform layer thickness or
volume (GCIP or sometimes GCIPL) regularly complements
the pRNFL as an imaging marker. The main targets of interest
are the very ganglion cell bodies associated with axons in the
retinal fiber layers described previously. Due to the poor dif-
ferentiability in OCT imaging, the ganglion cell layer is usu-
ally measured in combination with the adjacent inner plexi-
form layer as GCIP (Fig. 1). The GCIP is mostly measured as
the perifoveal volume (in mm3), since the ganglion cells are
highly concentrated parafoveally and account for about 34%
of the macular volume [78, 82, 83]. Up to 3 months after acute
ON when the pRNFL is regularly affected by swelling, the
GCIP serves especially well as a stable parameter to quantify
retinal neuro-axonal damage [84–87]. Recently, the inner nu-
clear layer (INL) was suggested to have a swelling specific to
an inflammation in autoimmune disorders of the CNS that
present with ON [88–91]. The outer retinal layers are currently
of lesser interest in neuroinflammatory diseases. Although
changes have been described, e.g., after ON or branch retinal
artery occlusion in Susac syndrome, high vulnerability to var-
iability from imaging, such as patient positioning and poor
reproducibility, makes the interpretation of the outer retinal
layer measurements challenging [60, 92, 93].
Retinal measurements betweenOCT devices from different
manufacturers are usually not comparable. Whereas, pRNFL
has a reasonably good standardization and is measured simi-
larly across devices, GCIP and INL measurements lack this
standardization, thereby impeding comparability [94]. The es-
tablishment of standardized criteria for acquisition and assess-
ment of OCT images like the OSCAR-IB criteria for image
quality [95, 96] and the APOSTEL reporting guidelines for
studies incorporating OCT strive to improve comparability of
retinal layer quantification longitudinally, as well as across
cohorts [97].
NMOSD and OCT
Characteristics of ON as the most common
manifestation of NMOSD
ON is the first clinical feature observed in about 55% of the
patients with NMOSD and usually causes severe structural
damage to the optic nerve and retina with resulting functional
impairment [98]. NMOSD patients often suffer from bilateral
and sometimes simultaneous ON (radiological bilateral ON:
MS ~ 20%, NMOSD ~ 80%), frequent relapses, and severely
reduced visual acuity or even complete vision loss [98].
Unilateral ON often appears as afferent pupillary defect
(RAPD), while this can be concealed in bilateral ON [99].
Typically, subacute visual loss progresses in the course of days
or weeks, and recovery is possible within 6months since onset
[100, 101]. One year after ON, only 52% of the NMOSD
patients recover a high contrast visual acuity of 20/20 to 20/
63, and about 25% suffer from visual impairment with acuity
of < 20/200 [102–104]. Apart from a high contrast visual acu-
ity, patients are often afflicted with severe loss of low contrast
visual acuity and decreased vision-related quality of life [105,
106].
Neuro-axonal damage of the retina after ON
So far, no published studies have investigated acute ON
specifically in NMOSD. Studies investigating isolated or
idiopathic acute ON, without the distinction of underlying
pathologies, have shown that during clinical onset of acute
ON, OCT measurements typically give a highly swollen
pRNFL that is not representative of retrograde axonal dam-
age [107]. At this time, GCIP thickness is similar in both
the affected and the unaffected fellow eye (Table 1) [86].
After acute ON, the loss of retinal axons and ganglion cells
proceeds over a period of 6 months [89, 106]. Since the
optic nerve is often affected near the chiasm in the AQP4-
ab positive NMOSD, potential carryover affects could ra-
diologically or clinically impact the contralateral optic
nerve after the unilateral ON [98]. Recurrent ONs in
NMOSD give rise to severely thinned pRNFL and GCIP
(Fig. 2) [122]. In the case of severe optic nerve atrophy
resulting from multiple ON attacks, with pRNFL values
lower than 30 μm, further neuro-axonal loss is hard to
detect due to flooring effects [99] and the influence of
retinal blood vessels running through the measured layers
[123]. While retinal damage after ON in MS exhibits a
temporal preponderance, all segments can be affected in
NMOSD [106, 124]. Pattern variances between NMOSD
subtypes are still under investigation: a recent publication
suggests a temporal preponderance of retinal damage in
MOG-ab seropositive patients as well [111]. Single ONs
seem to have less severe effects in MOG-ab seropositive
patients compared to AQP4-ab seropositive patients; al-
though the higher frequency of ONs in MOG-ab seropos-
itive patients may result in similar long-range prognoses
and may still be unfavorable with respect to visual out-
come [119, 125]. After ON, high-contrast visual acuity
and low-contrast visual acuity impairment are highly cor-
related cross-sectionally with reduced pRNFL and GCIP,
suggesting both imaging markers as appropriate structural
correlates for visual function loss [100, 106, 113, 114].
Relapsing ONs cause pathological latencies of visual
evoked potentials (VEP) and severe visual impairment up
to complete vision loss [119, 126].
Primary retinal pathology in NMOSD
Around 20% of the NMOSD patients have microcystic
alterations of the INL after ON (Fig. 3) [89, 90, 109,
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127]. This so-called microcystic macular edema (MME) is
characteristic for a range of optic neuropathies and is not
specific for NMOSD. It has also been reported, although
not as frequently, in MS patients with ON and from pa-
tients with non-inflammatory optic neuropathies [90, 128,
129]. Its formation in NMOSD seems to be dynamic and
Table 1 Most important recent publications on OCT in NMOSD
Reference Study patients Controls Findings
[108] N = 30, 66% AQP4-ab-p. No ↓ pRNFL only in NMOSD with past ON over 18
months follow-up, independent from relapses
[102] N = 29, 48% AQP4-ab-p., 100%
ON, and LETM
N(HC) = 45
N(LETM only) = 29
N(MS-ON) = 29
N(MS-NON) = 44
↓ pRNFL in NMOSD vs. all other groups
↓ pRNFL after ON in NMOSD vs. MS
↓ GCIP in NMOSD vs. HC and LETM
↑ INL in NMOSD vs. HC
[109] N = 25, 100% AQP4-ab-p. No Microcystic alterations in INL in 15% of the eyes and
24% of the eyes after ON
[110] N = 21, 90% AQP4-ab-p. N(HC) = 34 Time since onset +~ atrophy of gray matter
pRNFL +~ pericalcarine cortex thickness
[111] N(AQP4-ab-p.) = 19
N(MOG-ab-p.) = 13
N(HC) = 13 ↓ pRNFL in MOG-ab-p. vs. AQP4-ab-p. NMOSD
temporal atrophy in MOG-ab-p. NMOSD
[112] N = 72, 69% ON N(HC) = 34 ↓ fovea thickness in NMOSD with and without ON vs.
HC; foveal thickness +~ low contrast VA
[113] N = 15, 100% AQP4-ab-p. N(HC) = 23
N(MS) = 15
↓ pRNFL, high contrast and low contrast VA in NMOSD
vs. MS and HC
[114] N = 33, 100% ON, 52% AQP4-ab-p. N(HC) = 41
N(MS) = 60
N(LETM) = 28
↓ pRNFL and high contrast VA in NMOSD after ON vs.
all other groups
↓ pRNFL in LETM vs. HC
[115] N = 18, 100% ON, 100% AQP4-ab-p. N(MS) = 14 ↓ pRNFL in NMOSD vs. MS
pRNFL +~ high contrast VA
pRNFL −~ number of attacks and −~ time until high-dose
corticosteroid treatment
[116] N = 31, 71% ON, 100% AQP4-ab-p. N(HC) = 34 ↓ foveal thickness and FA in NMOSD with and without
ON vs. HC
↓ pRNFL in NMOSD only after ON vs. HC
[50] N = 40, 92, 5% AQP4-ab-p. No Vessel artifacts in pRNFL measurements −~ pRNFL
[72] N = 23, 70% ON, 56% AQP4-ab-p. N(HC) = 75
N(MS) = 110
= pRNFL in NMOSD and MS after ON
↓ temporal pRNFL without ON in MS vs. NMOSD
↓ pRNFL and GCIP in NMOSD without ON vs. HC
[117] N = 9, 100% ON, 67% AQP4-ab-p. No No RNFL or macular thinning observed over 4 years follow-up
[118] N = 22, 77% ON, 100% AQP4-ab-p. N(MS) = 47 ↓ pRNFL after ON in NMOSD vs. to MS
More severe superior and inferior affection in NMOSD
[119] N(AQP4-ab p.) = 16
N(MOG-ab-p.) = 16
N(HC) = 16 ↓ pRNFL, GCIP, high contrast VA in AQP4-Ak-p., and
MOG-ab-p. NMOSD vs. HC
= structural and functional parameters in AQP4-ab-p. vs. MOG-ab-p.
NMOSD
↑ ON rate in MOG-ab-p. vs. AQP4-ab-p. NMOSD
[120] N = 26, 100% ON, 60% AQP4-ab-p. N(HC) = 77
N(MS) = 378
N(LETM) = 17
↓ pRNFL and TMVafter ON in NMOSD vs. to MS
= pRNFL and TMV in non-ON NMOSD eyes and HC
[105] N = 31, 74% ON, 65% AQP4-ab-p. N(MS) = 31 ↓ vision-related quality of life in NMOSD vs. MS vision-related quality
of life +~ high contrast and low contrast VA and pRNFL and GCIP
[106] N = 17, 60% ON, 94% AQP4-ab-p. N(HC) = 17
N(MS) = 17
↓ pRNFL, GCIP and low contrast VA in NMOSD vs. HC
↑ INL and outer retinal layers in NMOSD after ON vs. NMOSD
without ON, MS, and HC
[89] N = 39 N(HC) = 39 ↓ pRNFL, GCIP, outer retinal layers, and low contrast VA in NMOSD
vs. HC microcystic INL alterations in 26% of the NMOSD patients
(after ON only)
[121] N(MOG-ab-p) = 6 N(AQP4-ab-p.) = 10 ↓ pRNFL and VA after ON in AQP4-ab-p. vs. MOG-ab-p. NMOSD
[86] N = 22, 73% AQP4-ab-p. N(HC vs. NMOSD) = 22
N(HC vs. MS) = 50
N(MS) = 98
N(acute ON) = 20
↓ pRNFL, GCIP, and TMVafter ON vs. without ON in NMOSD
and MS
↓ GCIP in non-ON NMOSD vs. HC
N number, vs. versus, ↓ reduction, ↑ increase, +~ positive correlation, -~ negative correlation, pRNFL peripapillary retinal nerve fiber layer, GCIP
combined ganglion cell and inner plexiform layer, INL inner nuclear layer, ON optic neuritis, AQP4-ab-p. aquaporin-4 antibody positive, FA fractional
anisotropy, HC healthy controls, LETM longitudinally extensive transverse myelitis,MSmultiple sclerosis,MOG-ab-p. myelin oligodendrocyte glyco-
protein antibody positive, VA visual acuity
24 EPMA Journal (2018) 9:21–33
caused through intraretinal processes, although vitreous
traction might play an additional role in some cases
[127, 130]. The detailed pathology of MME is not yet
clear; possible explanations include vascular damage
with extracellular fluid accumulation, the aforemen-
tioned vitreous traction and Mueller cell pathology
[128, 127, 131].
Mueller cells are astrocytic cells of the retina residingmain-
ly in the INL and might also play a role in NMOSD beyond
MMO and ON-inflicted damage. They have multiple respon-
sibilities, including water homeostasis, energy metabolism,
and neurotransmitter recycling. Since they express AQP4 wa-
ter channel proteins, they might be a direct target of AQP4-ab
and a potential cause of a primary retinopathy in NMOSD
[132–134]. Animal studies and human autopsy reports sup-
port the concept of NMOSD as a primary astrocytopathy. In
one study, a retinal damage model in rats showed
complement-independent loss of AQP4 in Mueller cells
[132]. Autopsies of the afferent visual system demonstrated
complement-independent loss of retinal Müller cells also in
humans [135]. This is further substantiated by in vivo data
from the fovea in NMOSD, where Mueller cells reside in high
concentration. In AQP4-ab seropositive NMOSD, the foveal
and parafoveal regions are thinned while the pRNFL and the
GCIP seem to be unaffected in patients without a history of
ON (Fig. 3) [112, 116]. The presumed primary retinopathy
could potentially enable a quicker diagnosis and sensible
tracking of disease course in the future, but research in this
regard is still lacking [136, 137]. While a recent study by Tian
et al. [138] found that there is also retinal neuro-axonal dam-
age without ON in NMOSD, longitudinal studies investigat-
ing neuro-axonal damage without ON in NMOSD have not
been performed extensively. The only two studies published
so far have shown conflicting results, where Bouyon et al.
[108] showed RNFL thinning over 18 months in patients with
a past ON, but Manogaran et al. [117] were not able to show
RNFL or macular thinning over a 4-year follow-up. Thus,
further longitudinal studies are required, to investigate the
development of retinal damage in NMOSD beyond ON and
their potential functional relevance.
Fig. 2 Neuro-axonal damage
after ON in NMOSD forA an eye
not affected byON in an NMOSD
patient compared toB an eye after
one single ON in an NMOSD
patient andC an eye after multiple
ONs of an NMOSD patient. (1)
TMVaround the fovea with (2)
corresponding macular volume of
represented segments. (3)
Peripapillary ring scan around the
optic nerve head with marked
retinal nerve fiber layer for
pRNFL measurements. (4) Color-
coded image of the pRNFL
thicknesses compared to a healthy
cohort from the device’s
normative database: green: not
reduced compared to a healthy
cohort (> fifth percentile), yellow:
borderline thinned compared to a
healthy cohort (< fifth percentile),
red: severely reduced compared
to a healthy cohort (< first
percentile). ON optic neuritis,
NMOSD neuromyelitis optica
spectrum disorders, pRNFL
peripapillary retinal nerve fiber
layer, TMV total macular volume
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Association between OCT and magnetic resonance
imaging
The magnetic resonance imaging (MRI) of brain and spinal
cord is an indispensable tool and a part of the diagnostic
criteria for MS and NMOSD [4, 139–144]. In NMOSD, the
association between brain tissue alterations and intraretinal or
afferent visual system changes is not completely understood.
Retrograde and anterograde trans-synaptic degeneration fol-
lowing ON potentially causes subsequent alterations in the
retina, optic nerve, and anatomically connected tracts
[145–148]. Consequently, a combination of lesion length in
the optic nerve measured byMRI and retinal findings by OCT
offers the unique possibility of predicting visual outcome after
ON [125]. Recently, a study with a mixed AQP4-ab seropos-
itive and seronegative NMOSD cohort that had cortical atro-
phy showed a correlation between pRNFL and pericalcarine
cortex thickness, further supporting the concept of trans-
synaptic degeneration being responsible for some detectable
brain atrophy [110]. Also, intracerebral changes are
accentuated in the optic radiation and can consequently be
understood as ON-associated transmitted damage [149].
Nevertheless, a functional MRI study by Finke et al. suggests
that not only are there degenerative processes that contribute
to impaired vision in NMOSD but maladaptive plasticity after
ON may also play a role [150].
While numerous studies exist describing brain tissue alter-
ations in MS (global atrophy, atrophy of grey and white mat-
ter, microstructural changes by diffusion-weighted imaging
(DWI)), only few studies have investigated MRI characteris-
tics in NMOSD [149, 151–154]. The existence of diffuse tis-
sue alterations with global or regional atrophy in NMOSD is
therefore still a matter of debate [155, 156]. Up to 80% of the
AQP4-ab seropositive NMOSD patients present with cerebral
lesions in AQP4-rich sites like the hypothalamus and
periependymal regions; where up to 15% would formally ful-
fil the diagnostic criteria for MS [157, 158]. In contrast toMS,
cortical lesions are rare in NMOSD [159, 160]. Joint analyses
of diffusion tensor imaging of the optic radiation and OCT
data from AQP4-ab seropositive patients suggest microstruc-
tural damage of the afferent visual system also in patients
without a history of ON, supporting diffuse brain changes
detectable by MRI outside of trans-synaptic degeneration
[116, 138]. In line with this, a study from Ventura et al.
showed a spinal cord atrophy in patients without LETM and
spinal cord lesions, which points towards an attack-
independent tissue damage in the spinal cord [161].
Ultimately, the latter three studies included only a few patients
and further studies investigating attack-independent tissue al-
terations in NMOSDwith higher sample sizes and in different
anatomical regions are highly warranted.
The relevance of OCT for clinical trials in NMOSD
To date, no results from randomized controlled trials (RCTs)
of disease-modifying therapies (DMTs) in NMOSD have been
published. Current treatment strategies (e.g., rituximab, aza-
thioprine, mycophenolate mofetil, oral prednisolone, recently
also tocilizumab) are based on retrospective case series or
uncontrolled trials [29, 30, 33–37]. Importantly, DMTs used
in MS (e.g., beta-interferon, glatiramer acetate, natalizumab,
fingolimod, alemtuzumab) are ineffective in NMOSD patients
or can even provoke relapses [31, 32, 162]. Therefore, the
development of safe and effective DMTs for NMOSD is high-
ly warranted [163, 164]. Several RCTs in this regard are cur-
rently conducted or planned [165–167]. In these and future
trials, OCT may serve as a valuable outcome parameter to
evaluate the structural sequelae of ON attacks or to track sub-
clinical retinal changes. To date, multiple RCTs inMS and ON
have successfully used OCTmeasures like pRNFL as primary
or secondary endpoints [73, 168, 169]. In NMOSD, smaller
retrospective studies evaluating the effect of therapies based




Fig. 3 Primary retinal pathology in NMOSD. A Macular microcysts in
the INL of a NMOSD after ON (arrows: microcysts). B (1) OCT and (2)
mean shape surface reconstruction with shape variation (color code:
thickness in mm + 1 SD) of healthy cohort compared to C (1) OCT and
(2) mean shape surface reconstruction with shape variation of broadened
fovea surface in a NMOSD cohort. ON optic neuritis, NMOSD
neuromyelitis optica spectrum disorders, INL inner nuclear layer, SD
standard deviation
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superiority of the combination of plasmapheresis and cortico-
steroid therapy compared to corticosteroid therapy alone and
confirmed a preserving effect on RNFL of early high-dose
methyl prednisolone therapy in acute ON [113, 115]. Future
RCTs in NMOSD may incorporate the predictive value of
structural OCT parameters for visual function in parallel to
common clinical endpoints, such as pRNFL and GCIP as
markers of neuro-axonal damage and INL as a marker for
inflammation [84, 170].
Outlook
The retina is one of the most affected CNS regions in
NMOSD. The OCT is an easy-to-use diagnostic tool to assess
neuroinflammatory and neurodegenerative processes in the
retina and thus the visual system. An early examination of
the retina by OCT in NMOSD might provide useful informa-
tion on the severity of structural damage that may be predic-
tive of functional outcomes, as well as in the long-term disease
course [171]. With regard to NMOSD-specific pathology,
OCT measurements can also provide key information for dif-
ferential diagnosis against other disease entities. In the future,
OCT might also help to evaluate the success of NMOSD-
specific therapies. Adequately powered studies investigating
longitudinal changes both after ON in NMOSD but also out-
side ON are currently lacking and should be a priority of
future research.
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